WebApr 5, 2024 · SVP Investor Relations, Orkla ASA. [email protected] +47 95 07 51 14. Email Alerts. To opt-in for investor email alerts, please enter your email address in the field below and select at least one alert option. After submitting your request, you will receive an activation email to the requested email address. ... Quarterly Report: Annual ... WebDescription. This report, filed with the SIX Swiss Exchange in Switzerland, provides a comprehensive overview of Novartis, including our company structure, corporate …
Q1 2024 Results - Novartis
WebApr 14, 2024 · 20 years & counting! That’s how many years Advanced Accelerator Applications has pioneered in nuclear medicine imaging and therapy. As part of the Supply Chain and Customer Relations Team this role is critical in ensuring timely and safe delivery of medication to Canadian patients. Advanced Accelerator Applications, a Novartis … WebAll Lonza Investor Relations reports and presentations available in the Reporting Center. Our Offering. Biologics. Mammalian. Microbial. ADCs / Bioconjugates. Drug Product. ... Investor Relations. Shareholder Information. Agenda and Events. Financial Reporting. Annual Report. Corporate Governance. Ethics and Compliance. Investor Inquiries. smallshaw shrewsbury
Financial Reports AbbVie
WebApr 11, 2024 · Below is Validea's guru fundamental report for NOVARTIS AG (ADR) (NVS). Of the 22 guru strategies we follow, NVS rates highest using our Multi-Factor Investor model based on the published strategy ... WebSep 22, 2024 · Novartis Investor Relations Central investor relations line: +41 61 324 7944 E-mail: [email protected] WebInvestor Contacts Novartis Home Contacts Investor Contacts Investor Contacts For questions about Investor Relations or the Share Registry, please contact our team. For all other queries: Main Switchboard Switzerland Phone: +41 61 324 11 11 US Switchboard Phone: +1 862 778 21 00 Share Registry IR Europe IR North America smallshaw road rochdale